Enveric Biosciences Inks Two Licensing Agreements With Restoration Biologics To Treat Joint Disease [Benzinga]
Tuesday, February 4, 2025 1 min read
Key Takeaway: Enveric Biosciences, through its subsidiary Akos Biosciences, has signed two licensing agreements with Restoration Biologics. These agreements involve cannabinoid-COX-2 conjugate compounds aimed at treating joint disease. The collaboration suggests a focus on both pharmaceutical and non-pharmaceutical applications.
Price reaction · baseline $21.72 (2025-02-03 close) · hit pre-market · 1 other ENVB headline(s) in the window, move may be shared
day 0 close
-3.9%
Market Sentiment Analysis
POSITIVE FACTORS
Enveric Biosciences has secured two licensing agreements.
The agreements focus on innovative treatments for joint disease.
Collaboration with Restoration Biologics enhances Akos' portfolio.
Full Press Release Details
On Tuesday, Enveric Biosciences’ wholly-owned subsidiary, Akos Biosciences, Inc., entered into two licensing agreements with Restoration Biologics LLC, a biotechnology company focused on treating joint disease. The companies have executed two licenses for Akos’ cannabinoid-COX-2 conjugate compounds for pharmaceutical and potential non-pharmaceutical applications.
Full Article >>
Frequently Asked Questions
What companies are involved in the licensing agreements?
The licensing agreements involve Enveric Biosciences and Restoration Biologics.
What is the focus of the licensing agreements?
The agreements focus on cannabinoid-COX-2 conjugate compounds for joint disease.
Who is Akos Biosciences?
Akos Biosciences is a wholly-owned subsidiary of Enveric Biosciences.
What type of applications are being explored?
The agreements cover both pharmaceutical and potential non-pharmaceutical applications.